2015-11-09T16:44:35-06:00 2014-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 650N BETHESDA MD 208142930 990 2014-01-01 830431851 PATH VACCINE SOLUTIONS PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2015-11-09 1 3019519090 2014 2016-03-07 17:11:31Z OLIVIA POLIUS 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 45322297 0 X WWW.PATH.ORG X 2006 WA SEE PART III, LINE 1. 7 2 0 0 0 0 58520241 24448784 1200 0 875409 315733 2365 7237 59399215 24771754 28816531 36562862 0 0 0 0 0 0 0 8673859 10606165 37490390 47169027 21908825 -22397273 166859076 149044550 6024155 10278308 160834921 138766242 X THE MISSION OF PATH VACCINE SOLUTIONS (PVS) IS TO IMPROVE THE HEALTH OF CHILDREN IN LOW-INCOME COUNTRIES BY ACCELERATING THE DEVELOPMENT OF VACCINES THAT WILL BE EFFECTIVE AND AFFORDABLE FOR THOSE WHO NEED THEM MOST. FROM INITIAL DISCOVERY THROUGH CLINICAL TRIALS, PVS WORKS WITH COMMERCIAL PARTNERS, SUCH AS VACCINE MANUFACTURERS AND BIOTECHNOLOGY FIRMS, AND NONPROFIT PARTNERS, SUCH AS UNIVERSITIES AND RESEARCH INSTITUTIONS, TO SHORTEN THE TIMELINE FOR VACCINE DEVELOPMENT.PVS WORKS WITH PARTNERS TO DEVELOP NEW VACCINES BY PROVIDING FUNDING AND EXPERTISE IN PRECLINICAL DEVELOPMENT, MANUFACTURING, AND CLINICAL DEVELOPMENT, WITH A FOCUS ON LOW-RESOURCE COUNTRIES. IN RETURN, PARTNERS AGREE TO TERMS THAT HELP ENSURE THE RESULTING PRODUCTS ARE AFFORDABLE AND AVAILABLE IN DEVELOPING COUNTRIES. 0 0 47169027 36562862 PVS WORKS TO PREVENT DEATH AND DISEASE CAUSED BY PNEUMONIA, INFLUENZA, RESPIRATORY SYNCYTIAL VIRUS, POLIO, AND DIARRHEA AMONG CHILDREN AROUND THE WORLD. WE ACCELERATE THE DEVELOPMENT OF SAFE, EFFICACIOUS, AND AFFORDABLE VACCINES IN PARTNERSHIP WITH PUBLIC AND PRIVATE GROUPS. IN 2014, PVS MARKED A SIGNIFICANT MILESTONE IN OUR WORK TO REDUCE CHILDHOOD DEATHS DUE TO DIARRHEAL DISEASE, WHICH IS THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN THE DEVELOPING WORLD. OUR DECADE-LONG PARTNERSHIP WITH INDIAN VACCINE MANUFACTURER BHARAT BIOTECH TO DEVELOP A VACCINE AGAINST ROTAVIRUS, THE LEADING CAUSE OF SEVERE CHILDHOOD DIARRHEA, LED TO THE INDIAN GOVERNMENT'S 2014 LICENSURE OF THE VACCINE AND ANNOUNCEMENT OF ITS INCLUSION IN THE NATIONAL IMMUNIZATION PROGRAM. THROUGH THE YEARS, PVS PLAYED A SIGNIFICANT ROLE IN THIS EFFORT. THROUGH A UNIQUE PUBLIC-PRIVATE PARTNERSHIP, WE PROVIDED TECHNICAL ASSISTANCE THAT ACCELERATED CLINICAL DEVELOPMENT OF THIS IMPORTANT VACCINE.OUR EVALUATION OF VACCINES TO FIGHT PNEUMONIA, THE LEADING CAUSE OF CHILDHOOD DEATHS WORLDWIDE, ADVANCED WITH THE INITIATION OF PHASE 1/2 TRIALS IN AFRICA. IN THE GAMBIA, WE ARE EVALUATING A 10-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-10), MANUFACTURED BY SERUM INSTITUTE OF INDIA, LTD. THE PCV-10 CANDIDATE IS DESIGNED TO BE AFFORDABLE AND FOCUSES ON VARIETIES OF THE PNEUMOCOCCUS BACTERIUM THAT ARE PREVALENT IN DEVELOPING COUNTRIES OF AFRICA. IN KENYA, WE ARE STUDYING A PNEUMOCOCCAL WHOLE CELL VACCINE THAT HAS POTENTIAL TO PROTECT CHILDREN AGAINST SEVERAL SEROTYPES OF PNEUMOCOCCAL DISEASE.ALSO IN 2014, PVS MARKED THE SUCCESSFUL COMPLETION OF IMPORTANT CLINICAL STUDIES TO EVALUATE AND OPTIMIZE INFLUENZA VACCINE. TRIALS IN BANGLADESH AND SENEGAL GENERATED EFFICACY AND ADDITIONAL SAFETY DATA ON THE SEASONAL LIVE, ATTENUATED INFLUENZA VACCINE AMONG CHILDREN AS YOUNG AS TWO YEARS OF AGE. THIS YIELDED IMPORTANT NEW INSIGHTS INTO THE PROTECTION OF YOUNG, VULNERABLE CHILDREN IN DEVELOPING COUNTRIES. ADDITIONALLY, A PHASE 1 STUDY OF THE LIVE, ATTENUATED A/H2N2 INFLUENZA VACCINE SUCCESSFULLY CONCLUDED IN 2014. 47169027 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 X 7 2 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 WA X X OLIVIA POLIUS CHIEF FINANCIAL OFFICER 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 STEVEN B DAVIS CHAIR 1.00 39.00 X X 0 569984 43512 PENNY HEATON VICE CHAIR 1.00 0.00 X X 0 0 0 OLIVIA D POLIUS TREASURER 1.00 39.00 X X 0 255770 39644 AMIE E BATSON DIRECTOR 1.00 39.00 X 0 275229 32472 DANIEL LASTER DIRECTOR / GENERAL COUNSEL 1.00 39.00 X 0 250848 39180 DAVID C KASLOW DIRECTOR 1.00 39.00 X 0 378301 41432 CHRIS KARP DIRECTOR 1.00 0.00 X 0 0 0 DAVID A ALLI SECRETARY 20.00 20.00 X 0 156435 28858 0 1886567 225098 0 0 1 0 NORTHERN TRUST 50 S LASALLE ST CHICAGO IL 60675 ASSET MANAGEMENT 182113 1 24448784 24448784 866276 866276 20000000 20550543 -550543 -550543 -550543 OTHER REIMBURSEMENTS 900099 7237 7237 7237 24771754 0 0 322970 26167231 26167231 10395631 10395631 26292 26292 182114 182114 518991 518991 3532 3532 245180 245180 12575 12575 5000 5000 1866812 1866812 80056 80056 179375 179375 SUBCONTRACTORS 7163022 7163022 LAB SUPPLIES 217659 217659 EQUIPMENT R&M 55773 55773 STORAGE 32676 32676 17108 17108 47169027 47169027 0 0 5006227 15650996 69342564 60119568 217893 126845 32953 227541 63833 6934 163708 92252505 72983433 166859076 149044550 6024155 10278308 6024155 10278308 X 150 37582 160834771 138728660 160834921 138766242 166859076 149044550 -22397273 328594 0 X 0 1 X 1 0 X X 1 PATH 911157127 BOX 7 1 47169027 0 1 47169027 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 PART IV, SECTION A, LINE 6: PATH VACCINE SOLUTIONS PROVIDED VARIOUS GRANTS DETAILED IN SCHEDULES F AND I. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 227541 63833 163708 163708 1 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 261540 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 1172534 EUROPE 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 635222 EUROPE 0 0 GRANTMAKING 2811050 NORTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 38848 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 385829 RUSSIA AND NEIGHBORING STATES 0 0 GRANTMAKING 210356 SOUTH AMERICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 5479 SOUTH ASIA 0 10 PROGRAM SERVICES PRODUCT DEVELOPMENT 844547 SOUTH ASIA 0 0 GRANTMAKING 5590814 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES PRODUCT DEVELOPMENT 947134 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 610877 0 0 0 10 0 10 5520858 7993372 13514230 EAST ASIA AND THE PACIFIC PRODUCT DEVELOPMENT 1172534 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 52095 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 109786 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 230160 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 378357 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 1925000 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 15865 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT 153189 CHECK/WIRE RUSSIA AND NEIGHBORING STATES PRODUCT DEVELOPMENT 210356 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 7768 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 2175385 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 457534 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 189490 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 470647 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 942745 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 511471 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 258112 CHECK/WIRE SOUTH ASIA PRODUCT DEVELOPMENT 577662 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 15000 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 6584 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 100000 CHECK/WIRE SUB-SAHARAN AFRICA PRODUCT DEVELOPMENT 489293 CHECK/WIRE EUROPE PRODUCT DEVELOPMENT -56438 CHECK/WIRE 17 5 1 0 0 0 0 0 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. DISCRETIONARY ON-SITE VISITS ARE ALSO CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 1 ADVANCED BIOSCIENCE LABRATORIES INC 9800 MEDICAL CENTER DRIVE BUILDING D ROCKVILLE MD 20850 621242262 N/A 8680 PRODUCT DEVELOPMENT BIOPROCESS TECHNOLOGY CONSULTANTS INC 12 GILL STREET SUITE 5450 WOBURN MA 01801 100002382 N/A 9000 PRODUCT DEVELOPMENT BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 352940111 636005396 501(C)(3) 274401 PRODUCT DEVELOPMENT BOSTON CHILDREN'S HOSPITAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 440082 PRODUCT DEVELOPMENT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINNATI OH 45229 310833936 501(C)(3) 24762 PRODUCT DEVELOPMENT FHI 360 FHI 360 HEADQUARTERS 359 BLACKWELL ST SUITE 201 DURHAM NC 27701 941646278 501(C)(3) 1307219 PRODUCT DEVELOPMENT FINA BIOSOLUTIONS LLC 9430 KEY WEST AVE SUITE 200 ROCKVILLE MD 20850 205448275 N/A 131671 PRODUCT DEVELOPMENT HARVARD UNIVERSITY SCHOOL OF PUBLIC HEALTH INTERNATIONAL HEALTH 677 HUNTINGTON AVENUE BOSTON MA 02115 042103580 501(C)(3) 178855 PRODUCT DEVELOPMENT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 1428 MADISON AVENUE NEW YORK NY 10029 136171197 501(C)(3) 236089 PRODUCT DEVELOPMENT JHU BLOOMBERG SCHOOL OF PUBLIC HEALTH 615 N WOLFE STREET BALTIMORE MD 21205 131687001 501(C)(3) 21561 PRODUCT DEVELOPMENT JOHNS HOPKINS UNIVERSITY 615 N WOLFE STREET W1100 BALTIMORE MD 21205 131687001 501(C)(3) 1129609 PRODUCT DEVELOPMENT LIQUIDIA TECHNOLOGIES INC 419 DAVIS DRIVE SUITE 100 DURHAM NC 27713 201926605 N/A 170028 PRODUCT DEVELOPMENT NOVAVAX INC 20 FIRSTFIELD ROAD ROCKVILLE MD 20878 222716046 N/A 2804370 PRODUCT DEVELOPMENT OKLAHOMA STATE UNIVERSITY 203 WHITEHURST HALL STILLWATER OK 74078 736017987 501(C)(3) 39028 PRODUCT DEVELOPMENT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 501(C)(3) 138896 PRODUCT DEVELOPMENT TULANE EDUCATIONAL FUND 1430 TULANE AVENUE TB-32 NEW ORLEANS LA 701122632 720423889 501(C)(3) 90900 PRODUCT DEVELOPMENT UNITED STATES NAVAL MEDICAL RESEARCH CENTER 503 ROBERT GRANT AVE SILVER SPRING MD 209107500 470100048 GOVERNMENT 471558 PRODUCT DEVELOPMENT UNIVERSITY OF ALABAMA AT BIRMINGHAM 701 20TH STREET SOUTH AB 1170 BIRMINGHAM AL 35294 636005396 501(C)(3) 121437 PRODUCT DEVELOPMENT UNIVERSITY OF FLORIDA 219 GRINTER HALL PO BOX 115500 GAINESVILLE FL 326115500 596002052 501(C)(3) 15176 PRODUCT DEVELOPMENT UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 526002033 501(C)(3) 455971 PRODUCT DEVELOPMENT WALTER REED ARMY INSTITUTE OF RESEARCH 503 ROBERT GRANT DRIVE SILVER SPRING MD 20910 520664528 GOVERNMENT 2375896 PRODUCT DEVELOPMENT WASHINGTON UNIVERSITY ONE BROOKINGS DRIVE CAMPUS BOX 1054 1054 ST LOUIS MO 63130 430653611 501(C)(3) 134870 PRODUCT DEVELOPMENT PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 501(C)(3) 15586258 PRODUCT DEVELOPMENT 18 5 PART I, LINE 2: SUBRECIPIENTS ARE REQUIRED TO SUBMIT PROGRESS REPORTS, WHICH ARE REVIEWED BY RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS AND FOLLOW UP ON ANY CONCERNS. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL AND FINANCIAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. 0 0 0 0 0 0 0 0 0 STEVEN B DAVIS CHAIR 0 421692 0 147592 0 700 0 31000 0 12512 0 613496 0 0 OLIVIA D POLIUS TREASURER 0 255000 0 0 0 770 0 30281 0 9363 0 295414 0 0 AMIE E BATSON DIRECTOR 0 275004 0 0 0 225 0 31000 0 1472 0 307701 0 0 DANIEL LASTER DIRECTOR / GENERAL COUNSEL 0 250008 0 0 0 840 0 26668 0 12512 0 290028 0 0 DAVID C KASLOW DIRECTOR 0 377000 0 0 0 1301 0 28920 0 12512 0 419733 0 0 DAVID A ALLI SECRETARY 0 156435 0 0 0 0 0 17483 0 11375 0 185293 0 0 PART I, LINE 3 PATH VACCINE SOLUTIONS RELIES ON A RELATED ORGANIZATION, PATH, TO DETERMINE COMPENSATION. PATH USES THE FOLLOWING TO ESTABLISH COMPENSATION OF THE EXECUTIVE DIRECTOR: - INDEPENDENT COMPENSATION CONSULTANT - COMPENSATION COMMITTEE - COMPENSATION SURVEY OR STUDY - APPROVAL BY THE BOARD OR COMPENSATION COMMITTEE FORM 990, PART VI, SECTION B, LINE 11 THE FORM 990 WAS PREPARED BY THE OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE 990 WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CFO SIGNED THE RETURN. FORM 990, PART VI, SECTION B, LINE 12C PVS HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PVS BOARD MEMBERS AND OFFICERS MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. PVS DOES NOT HAVE EMPLOYEES. PVS IS A SUPPORTING ORGANIZATION TO PATH WITHIN THE MEANING OF IRC SECTION 509(A)(3), AND PVS CONTRACTS WITH PATH FOR MANAGEMENT SERVICES. PATH HAS A WRITTEN CONFLICT OF INTEREST POLICY UNDER WHICH ALL PATH BOARD MEMBERS, OFFICERS, AND STAFF ABOVE A DESIGNATED LEVEL MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL PVS AND PATH DISCLOSURE FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. FORM 990, PART VI, SECTION C, LINE 19 PVS'S FINANCIAL STATEMENTS, GOVERNING DOCUMENTS, AND CONFLICT OF INTEREST POLICY ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. PATH 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 911157127 GLOBAL HEALTH WA 501(C)(3) LINE 7 N/A 0 PATH DRUG SOLUTIONS 280 UTAH AVENUE SUITE 250 SAN FRANCISCO CA 94080 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 11A PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ N/A N/A PATH 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0